At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 219 enrolled
Drug / intervention
BMS-986288 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Malignant Tumors
In Brief
A Phase 2 clinical trial evaluating BMS-986288, Nivolumab, and 1 other intervention for Advanced Cancer. Completed, enrolled 219 participants across 40 sites in 7 countries.
Detailed Summary
The purpose of this study is to determine whether BMS-986288 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of select advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancer
CountriesArgentina, Canada, Chile, France, Italy, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartSep 2019
Primary CompletionAug 2024
TodayJul 2026
First PostedJun 21, 2019
Enrollment StartSep 6, 2019
Primary CompletionAug 31, 2024
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 7.0 years ago
Interventions
BMS-986288drug
Specified dose on specified days
Nivolumabdrug
Specified dose on specified days
Regorafenibdrug
Specified dose on specified days